<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00665808</url>
  </required_header>
  <id_info>
    <org_study_id>NN304-1951</org_study_id>
    <nct_id>NCT00665808</nct_id>
  </id_info>
  <brief_title>Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During &quot;Real-life&quot; Usage in Germany</brief_title>
  <official_title>Insulin Detemir (Levemir®) Versus Isophane (NPH) Insulin (Protaphane®) in Combination With Oral Antidiabetic Agents (OAD) in Patients With Diabetes Mellitus Type 2 Comparing Treatment Satisfaction, Diabetes-related and General Health-related Quality of Life, as Well as Diabetes-control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This NON INTERVENTIONAL OBSERVATIONAL STUDY is conducted in Europe. The purpose of this NON
      INTERVENTIONAL OBSERVATIONAL STUDY is to primarily investigate treatment satisfaction when
      using Levemir® versus Protaphane® in combination with OADs in daily settings.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>treatment satisfaction (DTSQs and DTSQc)</measure>
    <time_frame>over whole study duration, 24 weeks per patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>diabetes-related quality of life (ADDQoL)</measure>
    <time_frame>over whole study duration, 24 weeks per patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>general health-related quality of life (EQ-5D)</measure>
    <time_frame>over whole study duration, 24 weeks per patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>over whole study duration, 24 weeks per patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic control (HbA1c, fasting morning blood glucose)</measure>
    <time_frame>over whole study duration, 24 weeks per patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin dose</measure>
    <time_frame>over whole study duration, 24 weeks per patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concomitant diabetes therapy (OADs)</measure>
    <time_frame>over whole study duration, 24 weeks per patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>over whole study duration, 24 weeks per patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reactions, ADR</measure>
    <time_frame>over whole study duration, 24 weeks per patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse drug reactions, SADR</measure>
    <time_frame>over whole study duration, 24 weeks per patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy</measure>
    <time_frame>over whole study duration, 24 weeks per patient</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">8125</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin detemir</intervention_name>
    <description>Observational study on treatment satisfaction of Levemir ® versus Protaphane® during &quot;real-life&quot; usage in Germany</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Levemir®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isophane human insulin</intervention_name>
    <description>Observational study on treatment satisfaction of Levemir ® versus Protaphane® during &quot;real-life&quot; usage in Germany</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients willing and able to give signed informed consent; Patients with Type 2 diabetes
        mellitus; Patients, who should intensify treatment with long acting insulin in addition to
        their treatment with oral antidiabetic agents, due to insufficient blood glucose control;
        Patients with no regular use of short acting insulin (occasional use for correction is
        allowed); Patients with no contraindication for use of Protaphane® or Levemir®
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained from patient before first documentation of treatment
             in the observational study.

          -  Type 2 diabetes mellitus

          -  Patients, who should intensify treatment with long acting insulin in addition to their
             treatment with oral antidiabetic agents, due to insufficient blood glucose control

          -  No contraindication for use of Protaphane® or Levemir®

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mainz</city>
        <zip>55127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2008</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

